Pre-Test The Role of APs in the Treatment of NSCLC: Facilitating Effective Multidisciplinary Patient Management Strategies Pre-Test Data from the phase 3 MARIPOSA-2 study revealed that the combination of _____ and chemotherapy led to a significantly higher objective response rate (64%) than chemotherapy alone (36%) in patients with EGFR-mutated NSCLC (exon 19, L858R) who experienced disease progression on first-line osimertinib. Amivantamab Lazertinib Mobocertinib Nivolumab Unsure While an estimated 66% of patients receiving amivantamab experience an infusion reaction with the first dose, what percentage of patients experience a reaction with subsequent doses? 1% 11% 21% 31% Unsure How often do you recognize treatment-related adverse events and implement adverse event mitigation strategies for patients with NSCLC to minimize treatment interruptions? Always Often Sometimes Rarely Never How confident are you in your ability to provide guideline-directed NSCLC care? Very confident Confident Somewhat Confident Not very confident Not at all confident
